Home News

First quarter 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Wed, 13/05/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI and Moderna Announce Collaboration for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
ROVI and Moderna Announce Collaboration for Outside the United States Fill-...
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020
ROVI signs a co-operation agreement for a clinical trial to study the efficacy and safety of bemiparin in patients hospitalised with pneumonia caused by COVID-19
ROVI signs a co-operation agreement for a clinical trial to study the efficacy...
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has signed a co-operation agreement with Fundación de Investigación HM Hospitales to fund a...
2 min
14/04/2020